Analysis links SERMs to breast cancer prevention benefit

05/1/2013 | MyHealthNewsDaily.com · PhysiciansBriefing.com

Taking selective estrogen receptor modulators such as tamoxifen and raloxifene after menopause reduces by 38% a woman's risk of developing any kind of breast cancer for 10 years, according to an analysis of data from nine studies. The estrogen-blocking drugs particularly lowered the risk of estrogen-receptor positive breast cancer, researchers found. The study appeared online in The Lancet.

View Full Article in:

MyHealthNewsDaily.com · PhysiciansBriefing.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC